Publikationsdatenbank

A semisynthetic glycoconjugate provides expanded cross-serotype protection against Streptococcus pneumoniae (2022)

Art

Zeitschriftenartikel / wissenschaftlicher Beitrag

Autoren

Kaplonek, Paulina

Yao, Ling

Reppe, Katrin

Voß, Franziska

Kohler, Thomas

Ebner, Friederike (WE 6)

Schäfer, Alexander

Blohm, Ulrike

Priegue, Patricia

Bräutigam, Maria

Pereira, Claney L.

Parameswarappa, Sharavathi G.

Emmadi, Madhu

Ménová, Petra

Witzenrath, Martin

Hammerschmidt, Sven

Hartmann, Susanne (WE 6)

Sander, Leif E.

Seeberger, Peter H.

Quelle

Vaccine

Bandzählung: 40

Heftzählung: 7

Seiten: 1038 – 1046

ISSN: 0264-410x

Sprache

Englisch

Verweise

URL (Volltext): https://www.sciencedirect.com/science/article/pii/S0264410X21016765

DOI: 10.1016/j.vaccine.2021.12.068

Pubmed: 35033388

Kontakt

Institut für Immunologie

Robert-von-Ostertag-Str. 7-13
14163 Berlin
+49 30 838 51834
immunologie@vetmed.fu-berlin.de

Abstract / Zusammenfassung

Streptococcus pneumoniae (S. pneumoniae)infections are the leading cause of child mortality globally. Currentvaccines fail to induceaprotective immune response towards a conserved part of the pathogen,resulting in newserotypescausing disease. Therefore, new vaccinestrategies are urgently needed.Described is atwo-pronged approach combiningS. pneumoniaeproteins, pneumolysin (Ply) and pneumococcal surface protein A (PspA),with aprecisely defined synthetic oligosaccharide,wherebythe carrier protein actsas a serotype-independent antigen to provideadditional protection. Proof of concept in mice and swine modelsrevealed thatthe conjugatesinhibited colonization of the nasopharynx, decreased the bacterial load and reduced disease severity in the bacteria challenge model. Immunization of piglets provided the first evidence for the immunogenicity and protective potential of synthetic glycoconjugate vaccine in a large animal model.Acombination of synthetic oligosaccharides with proteins from the target pathogen opens the path to create broadly cross-protective ("universal") pneumococcal vaccines.